argenx to Participate at Upcoming Investor Conferences

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced its management team's participation in two upcoming investor conferences in November 2024. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12 at 2:30 p.m. ET in Boston, and attend investor meetings at the Jefferies London Healthcare Conference on November 20-21 in London. A live webcast of the Guggenheim fireside chat will be available on the company's website, with a replay accessible for approximately 90 days.

November 5, 2024

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:

• Guggenheim Inaugural Healthcare Innovation Conference. Fireside chat on Tuesday, November 12, 2024 at 2:30 p.m. ET in Boston, MA.
  
  
• Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 20 and Thursday November 21, 2024 in London, UK.
  
  

A live webcast of the Guggenheim fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the fireside chat.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.

For further information, please contact:

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

FAQ

When is argenx (ARGX) presenting at the Guggenheim Healthcare Innovation Conference 2024?

argenx will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024, at 2:30 p.m. ET in Boston, MA.

Which investor conferences is argenx (ARGX) attending in November 2024?

argenx is attending two conferences: the Guggenheim Inaugural Healthcare Innovation Conference in Boston and the Jefferies London Healthcare Conference in London.

Where can I watch argenx's (ARGX) Guggenheim Conference presentation?

The live webcast of argenx's Guggenheim fireside chat can be accessed on the Investors section of the argenx website at argenx.com/investors, with a replay available for approximately 90 days.

When is argenx (ARGX) participating in the Jefferies London Healthcare Conference 2024?

argenx will participate in investor meetings at the Jefferies London Healthcare Conference on Wednesday, November 20 and Thursday, November 21, 2024, in London, UK.